Immediate Response to Allergic Reactions
Artesunate allergies typically present as hypersensitivity reactions, ranging from mild rash or itching to severe anaphylaxis with symptoms like hives, swelling, breathing difficulty, or low blood pressure. Stop artesunate administration immediately. Administer epinephrine (0.3-0.5 mg intramuscularly for adults) for anaphylaxis, followed by antihistamines (e.g., diphenhydramine 25-50 mg IV/IM) and corticosteroids (e.g., hydrocortisone 100 mg IV or methylprednisolone 40-125 mg IV). Provide supportive care: oxygen, IV fluids, bronchodilators if wheezing occurs, and monitoring in an ICU setting for severe cases.[1][2]
Premedication to Prevent Reactions
For patients with prior mild reactions or at high risk (e.g., history of drug allergies), premedicate before artesunate infusion. Common regimen: hydrocortisone 100 mg IV, chlorpheniramine (or diphenhydramine) 10 mg IV, and paracetamol 650 mg IV, given 30 minutes prior. This reduces incidence of type I hypersensitivity, reported in up to 4% of IV artesunate users in malaria treatment.[3][4]
Alternative Antimalarials if Allergic
Switch to non-artesunate options for severe malaria. Oral quinine plus doxycycline or clindamycin serves as first-line alternative in adults. For children or pregnant patients, oral quinine monotherapy or atovaquone-proguanil (Malarone) may be used, depending on regional guidelines. IV quinidine is an option if quinine unavailable, but monitor for QT prolongation.[5][6]
Why Reactions Happen and Testing Options
Artesunate triggers IgE-mediated reactions in susceptible individuals, possibly due to its lipid emulsion vehicle in IV formulations. Skin prick testing or intradermal tests can confirm allergy post-reaction, using diluted artesunate (1:100 to 1:10). Desensitization protocols exist for confirmed cases: rapid IV protocols with 12-step dilutions over 3-4 hours, starting at 1:1,000,000 dilution, achieving full dose tolerance in most patients under supervision.[7][8]
Cross-Reactivity Risks
Allergic patients may react to other artemisinin derivatives (artemether, arteether) due to structural similarity—avoid entirely. No cross-reactivity with quinine or unrelated antimalarials like lumefantrine.[9]
Sources
[1] WHO Guidelines for Malaria, 2023
[2] NEJM: Artesunate Hypersensitivity
[3] J Infect Dis: Premedication Efficacy
[4] CDC Malaria Treatment
[5] WHO Alternatives to Artemisinin
[6] Lancet Infect Dis: Non-Artemisinin Options
[7] Allergy: Artesunate Desensitization
[8] AAAAI Drug Desensitization Protocols
[9] Clin Infect Dis: Artemisinin Cross-Reactivity